These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16221318)

  • 1. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
    Mohr AM; Holcomb JB; Dutton RP; Duranteau J
    Crit Care; 2005; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of recombinant factor VIIa.
    Roberts HR; Monroe DM; Hoffman M
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
    Grounds RM; Bolan C
    Crit Care; 2005; 9 Suppl 5(Suppl 5):S29-36. PubMed ID: 16221317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NovoSeven for non-hemophilia hemostasis.
    Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
    Martinowitz U; Kenet G; Segal E; Luboshitz J; Lubetsky A; Ingerslev J; Lynn M
    J Trauma; 2001 Sep; 51(3):431-8; discussion 438-9. PubMed ID: 11535886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
    Martinowitz U; Michaelson M;
    J Thromb Haemost; 2005 Apr; 3(4):640-8. PubMed ID: 15842347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing with recombinant factor viia based on current evidence.
    Hedner U
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):35-9. PubMed ID: 14872419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
    Mathew P
    Thromb Haemost; 2004 Oct; 92(4):738-46. PubMed ID: 15467904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
    Hauser CJ; Boffard K; Dutton R; Bernard GR; Croce MA; Holcomb JB; Leppaniemi A; Parr M; Vincent JL; Tortella BJ; Dimsits J; Bouillon B;
    J Trauma; 2010 Sep; 69(3):489-500. PubMed ID: 20838118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
    Selin S; Tejani A
    Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa and the trauma patient.
    Criddle LM
    J Emerg Nurs; 2006 Oct; 32(5):404-8. PubMed ID: 16997029
    [No Abstract]   [Full Text] [Related]  

  • 19. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
    Stephens JM; Joshi AV; Sumner M; Botteman MF
    Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review.
    Grounds M
    Blood Rev; 2003 Sep; 17 Suppl 1():S11-21. PubMed ID: 14697209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.